Inari Medical Inc

Inari Medical Inc(NARI)の財務

$79.970

+0.040 (+0.05%)終値時点

NARI の収益構成

Inari Medical Inc (NARI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VTE, accounting for 94.8% of total sales, equivalent to $145.35M. Another important revenue stream is Emerging Therapies. Understanding this composition is critical for investors evaluating how NARI navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

NARI の収益性とマージン

Evaluating the bottom line, Inari Medical Inc maintains a gross margin of 85.43%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4.34%, while the net margin is -11.97%. These profitability ratios, combined with a Return on Equity (ROE) of -17.72%, provide a clear picture of how effectively NARI converts its operational activities into shareholder value.

NARI の同業比較

In the context of the broader market, NARI competes directly with industry leaders such as ITGR and SANM. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, NARI's gross margin of 85.43% stands against ITGR's 24.71% and SANM's 10.44%. Such benchmarking helps identify whether Inari Medical Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2024Q3
YoY:
+21.39%
153.39M
Total Revenue
FY2024Q3
YoY:
-415.29%
-6.66M
Operating Profit
FY2024Q3
YoY:
-680.87%
-18.37M
Net Income after Tax
FY2024Q3
YoY:
-720.00%
-0.31
EPS - Diluted
FY2024Q3
YoY:
-106.94%
-995.00K
Free Cash Flow
FY2024Q3
YoY:
-3.51%
85.43
Gross Profit Margin - %
FY2024Q3
YoY:
-95.53%
0.28
FCF Margin - %
FY2024Q3
YoY:
-578.80%
-11.97
Net Margin - %
FY2023Q4
-0.39
ROIC

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める